A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites
Phase 1
Active, not recruiting
- Conditions
- Allergy to House Dust MitesMedDRA version: 20.0Level: LLTClassification code: 10020419Term: House dust mite allergy Class: 10021428Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2022-500660-35-00
- Lead Sponsor
- Astellas Pharma Global Development Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method